Elena Ardini

3.9k total citations
38 papers, 1.6k citations indexed

About

Elena Ardini is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Elena Ardini has authored 38 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 20 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Elena Ardini's work include Lung Cancer Treatments and Mutations (11 papers), Cell Adhesion Molecules Research (8 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Elena Ardini is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Cell Adhesion Molecules Research (8 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Elena Ardini collaborates with scholars based in Italy, Belgium and United States. Elena Ardini's co-authors include Elena Casale, Fabio Zuccotto, Mauro Angiolini, Elda Tagliabue, Sylvie Ménard, Alessandra Magnifico, Maria I. Colnaghi, Arturo Galvani, Nicola Mongelli and Marina Veronesi and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Elena Ardini

38 papers receiving 1.5k citations

Peers

Elena Ardini

ONCOL

PRM

Roxana E. Iacob United States

Bi‐Ching Sang United States

Gerhard Siemeister Germany

Lian‐Sheng Li United States

Jimmy A. Blair United States

Sheri L. Moores United States

Vanessa C. Gray‐Schopfer United Kingdom

Jennifer L. Stamos United States

Jessie Villanueva United States

Frank Boschelli United States

Roxana E. Iacob United States

Elena Ardini

1.6k ×1.5

679 ×1.3

ONCOL

581 ×1.7

PRM

135 ×0.5

267 ×1.3

Citations per year, relative to Elena Ardini Elena Ardini (= 1×) peers Roxana E. Iacob

Countries citing papers authored by Elena Ardini

Since Specialization

Citations

This map shows the geographic impact of Elena Ardini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elena Ardini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elena Ardini more than expected).

Fields of papers citing papers by Elena Ardini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elena Ardini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elena Ardini. The network helps show where Elena Ardini may publish in the future.

Co-authorship network of co-authors of Elena Ardini

This figure shows the co-authorship network connecting the top 25 collaborators of Elena Ardini. A scholar is included among the top collaborators of Elena Ardini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elena Ardini. Elena Ardini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Braud, Filippo de, Lorenzo Pilla, Monica Niger, et al.. (2014). Rxdx-101, an Oral Pan-Trk, Ros1, and Alk Inhibitor, in Patients with Advanced Solid Tumors with Relevant Molecular Alterations. Annals of Oncology. 25. iv148–iv148. 7 indexed citations

Casuscelli, Francesco, Elena Ardini, Nilla Avanzi, et al.. (2013). Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases. Bioorganic & Medicinal Chemistry. 21(23). 7364–7380. 28 indexed citations

Borrello, Maria Grazia, Elena Ardini, Laura D. Locati, et al.. (2013). RET inhibition: implications in cancer therapy. Expert Opinion on Therapeutic Targets. 17(4). 403–419. 37 indexed citations

Ardini, Elena & Arturo Galvani. (2012). ALK Inhibitors, a Pharmaceutical Perspective. SHILAP Revista de lepidopterología. 2. 17–17. 20 indexed citations

Ardini, Elena, Paola Magnaghi, Paolo Orsini, Arturo Galvani, & Maria Menichincheri. (2010). Anaplastic Lymphoma Kinase: Role in specific tumours, and development of small molecule inhibitors for cancer therapy. Cancer Letters. 299(2). 81–94. 39 indexed citations

Bossi, R, Maria Beatrice Saccardo, Elena Ardini, et al.. (2010). Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors. Biochemistry. 49(32). 6813–6825. 126 indexed citations

Ardini, Elena, Maria Menichincheri, Cristina Ponti, et al.. (2009). Abstract A243: Characterization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer models. Molecular Cancer Therapeutics. 8(12_Supplement). A244–A244. 27 indexed citations

Zuccotto, Fabio, Elena Ardini, Elena Casale, & Mauro Angiolini. (2009). Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation. Journal of Medicinal Chemistry. 53(7). 2681–2694. 397 indexed citations

Dalvit, Claudio, et al.. (2004). Reliable high-throughput functional screening with 3-FABS. Drug Discovery Today. 9(14). 595–602. 54 indexed citations

10.

Dalvit, Claudio, et al.. (2003). A General NMR Method for Rapid, Efficient, and Reliable Biochemical Screening. Journal of the American Chemical Society. 125(47). 14620–14625. 96 indexed citations

11.

Modugno, Michèle, Elda Tagliabue, Elena Ardini, et al.. (2002). p53-dependent downregulation of metastasis-associated laminin receptor. Oncogene. 21(49). 7478–7487. 25 indexed citations

12.

Ardini, Elena, Roberto Agresti, Elda Tagliabue, et al.. (2000). Expression of protein tyrosine phosphatase alpha (RPTPα) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo. Oncogene. 19(43). 4979–4987. 65 indexed citations

13.

Magnifico, Alessandra, Elda Tagliabue, Elena Ardini, et al.. (1998). Heregulin β1 induces the down regulation and the ubiquitin‐proteasome degradation pathway of p185^HER2 oncoprotein. FEBS Letters. 422(2). 129–131. 17 indexed citations

14.

Tagliabue, Elda, Elena Ardini, Alessandra Magnifico, et al.. (1998). Formation of the 67-kDa laminin receptor by acylation of the precursor. Journal of Cellular Biochemistry. 69(3). 244–251. 105 indexed citations

15.

Ardini, Elena, Graziano Pesole, Elda Tagliabue, et al.. (1998). The 67-kDa laminin receptor originated from a ribosomal protein that acquired a dual function during evolution. Molecular Biology and Evolution. 15(8). 1017–1025. 112 indexed citations

16.

Casalini, Patrizia, Serenella M. Pupa, R. Vecchi, et al.. (1998). Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. Oncogene. 17(4). 425–432. 46 indexed citations

17.

Ardini, Elena, et al.. (1997). Co-regulation and Physical Association of the 67-kDa Monomeric Laminin Receptor and the α6β4 Integrin. Journal of Biological Chemistry. 272(4). 2342–2345. 81 indexed citations

18.

Lanzi, Cinzia, Romolo A. Gambetta, Graziella Pratesi, et al.. (1997). A cell and mechanism-based approach for the selection of EGF receptor inhibitors.. PubMed. 12(6). 515–24. 7 indexed citations

19.

Magnifico, Alessandra, Elda Tagliabue, Elena Ardini, et al.. (1996). Peptide G, Containing the Binding Site of the 67-kDa Laminin Receptor, Increases and Stabilizes Laminin Binding to Cancer Cells. Journal of Biological Chemistry. 271(49). 31179–31184. 41 indexed citations

20.

Tagliabue, Elda, Elena Ardini, Rita Pellegrini, et al.. (1996). Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cells. British Journal of Cancer. 74(9). 1427–1433. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact